Discover and share articles, posts, and links from across the web.
This stock could make you a fortune in the next two years, or lose you a whole lot of money.
AI is a valuable tool that could unlock significant value for these healthcare leaders and their shareholders.
Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.
The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.
Hims & Hers stock traded more than 40% higher after the deal was announced.
Eli Lilly's stock is a bit expensive, even with a bit of a decline this year.
The company incurred a loss in its most recent quarterly results.
Investors were clearly impressed by the medical device specialist's fourth-quarter performance.
On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player’s GLP-1 strategy, margins, and legal risk profile.
A handful of the industry's income-generating gems are hiding in plain sight.
Evommune has two autoimmune disorder treatments with blockbuster potential.
Nothing about the recent past, present, or foreseeable future seems all that compelling.
These companies' shares have fallen too far, offering investors an attractive opportunity.
These biotechs are slowly making a name for themselves.
ResMed is a leader in CPAP machines and other medical devices that help millions breathe better.
Current shareholders were thrown an unexpected curveball that they actually should have been expecting.
They are down, but they are not out.
Is there any upside left for this rising biotech?
The biotech made a dramatic flip into profitability in its final quarter of 2025.
The company is pursuing a Phase 3 trial in its most exciting pipeline drug, and investors are awaiting potentially exciting data by the end of September.
It's important to always be prepared.
The multi-cancer early detection (MCED) company delivered some extremely bad news to investors in February, but the stock may attract risk tolerant investors...
These companies are highly unlikely to go under, no matter what happens.
A new battle between these longtime rival companies will likely go the same way as their previous battles.
Intuitive Surgical business momentum has been spectacular recently. But what should investors make of the valuation?
Regeneron's science and its Dupixent revenue are paving the way for it to further expand its portfolio.
Not many things have gone right for Novo Nordisk recently, but this is one of them.
They are relatively safe wealth compounders.
The drugmaker is getting its mojo back.
It won't be easy to knock the company off its pedestal.
It's off to a pretty decent start.
This stock continues to benefit from GLP-1 tailwinds -- and now it trades at a reasonable valuation.
A new product approval may be right around the corner.
The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.
Only the best dividend stocks can achieve "king" status.
Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.
Eli Lilly's stock price is based on growth rates that might fall short.
The open lakehouse stack had one of its busiest weeks in months. Arrow Java 19.0.0 shipped and the community immediately proposed raising the Java floor to J...
Last week I found 86 orphaned processes eating 10.3 GB of RAM on my VPS. The week before that, my stall monitor fired because I went for a walk. And my own d...
Your team tried GPT-4 for compliance review. It works maybe 70% of the time. The other 30% is hallucinated policy references, missed terminology specific to ...
![[Meta-RL] We told an AI agent 'you can fail 3 times.' Accuracy went up 19%.](https://media2.dev.to/dynamic/image/width=1200,height=627,fit=cover,gravity=auto,format=auto/https%3A%2F%2Fdev-to-uploads.s3.amazonaws.com%2Fuploads%2Farticles%2Frhoby1exg1y14f3leoi7.png)
Most AI agents get one shot. They take a question, run a search or plan, give an answer, and move on. If the answer is wrong, that failure is lost. The agent...
Hi! Happy to join the platform :) Hope to understand how it works and start contributing with educational technical content!
I run 16 agent teams. Engineering, research, design, marketing, security — each team with 3-5 specialized agents working in parallel. On a busy day, that's 4...
Invitation: Now, I am officially active on X (Twitter). For new DevOps ideas, you can join me on X (Twitter) as well. Click Here Article Abstract: Right now,...
Real world assets tokenization explained: master the complete guide to tokenizing physical assets. Unlock liquidity, transparency & global access ✓
A brushtail possum was found peering out among the toy kangaroos and dingoes in a retail store in Hobart’s airport, delighting staff and customersA passenger...
The filing estimates that the merged entity will hold at least 473 million XRP at launch, including contributions from Ripple.